Skip to content

Role of Papaya Leaf extract in improving platelet counts in living donor liver transplant recipients

Efficacy and safety of Platelet augmentation using Carica Papaya Leaf Extract in Live Donor Liver Transplantation recipients â?? a pilot randomized controlled trial.

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030283
Enrollment
30
Registered
2021-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: - Health Condition 3: K703- Alcoholic cirrhosis of liver Health Condition 4: K754- Autoimmune hepatitis Health Condition 5: K721- Chronic hepatic failure Health Condition 6: C220- Liver cell carcinoma Health Condition 7: O- Medical and Surgical Health Condition 8: K746- Other and unspecified cirrhosis ofliver Health Condition 9: K743- Primary biliary cirrhosis Health Condition 10: K744- Secondary biliary cirrhosis Health Condition 11: K717- Toxic liver

Interventions

Intervention1: Carica Papaya Leaf Extract: 1100mg of Carica Papaya Leaf Extract given 3 times a day starting atleast 3 days and upto 2 weeks prior to planned date of liver transplant, and continued in

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consenting adults who are planned to undergo living donor liver transplant with platelet counts less than or equal to 75000/uL preoperatively

Exclusion criteria

Exclusion criteria: 1. patients who do not consent 2. ALF & ACLF 3. Pediatric Transplant recipients 4. History of allergy to papaya 5. Preoperative platelet counts >75000/uL 6. Recent history of DVT 7. Presence of portal vein thrombosis

Design outcomes

Primary

MeasureTime frame
Post-operative Day 7 platelet countsTimepoint: Baseline, 1 day prior to surgery, Post operative Day 1,2,3,4,5,6 and 7

Secondary

MeasureTime frame
IL-6 levelsTimepoint: on Post-operative Day 3 and post-operative day 7;Incidence of early allograft dysfunctionTimepoint: upto post-operative day 14;Incidence of prolonged post-operative drainageTimepoint: post-operative day 14;Intra-operative blood lossTimepoint: Day of liver transplant;Intra-operative transfusion requirementsTimepoint: Day of liver transplant;Pre-operative platelet countsTimepoint: 1 day prior to liver transplant;S. Thrombopoeitin levelsTimepoint: On Post-operative day 3 and post-operative day 7

Countries

India

Contacts

Public ContactDr Anubhav

Institute of Liver and Biliary Sciences

viniyendra@yahoo.co.uk9540946803

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026